1 In summary, we have combined the antigen specificities of two
2 In summary, we have defined a robust blood-derived type I IFN
3 In summary, we have demonstrated that the horizontal transfer
4 In summary, we have described a direct link from CFTR to Ezri
5 In summary, we have described the first systematic analysis o
6 In summary, we have determined the structure, tissue distribu
7 In summary, we have developed a novel in vitro system that pr
8 In summary, we have developed a novel PICV-based live vaccine
9 In summary, we have developed a reliable method for interroga
10 In summary, we have developed a tissue-like microgel array fo
11 In summary, we have developed and validated a widely accessib
12 In summary, we have discovered a novel host-pathogen interact
13 In summary, we have discovered that linker histone H1, simila
14 In summary, we have established a zebrafish model of ALD that
15 In summary, we have established and characterized faithful PD
16 In summary, we have established immunocompromised murine mode
17 In summary, we have established that 0.43-0.46% of the proteo
18 In summary, we have established the first primary human macro
19 In summary, we have explored the effects of beads size, conce
20 In summary, we have identified a BECN1 helical region that tr
21 In summary, we have identified a gene regulatory network asso
22 In summary, we have identified a naturally occurring mutation
23 In summary, we have identified a novel and constitutively act
24 In summary, we have identified a novel mechanism of ErbB2-med
25 In summary, we have identified a novel mechanism of P-Rex1 re
26 In summary, we have identified a novel mechanism of PLN-induc
27 In summary, we have identified a novel mechanism through whic
28 In summary, we have identified a novel role for Nod2 in obesi
29 In summary, we have identified a unique substrate-binding mot
30 In summary, we have identified ADDA 5 as a lead CcO inhibitor
31 In summary, we have identified and characterized a novel G pr
32 In summary, we have identified CCL2 as a novel KIT D816V-depe
33 In summary, we have identified five candidate prenyltransfera
34 In summary, we have identified for the first time two E3 liga
35 In summary, we have identified mutations in CEP83, another DA
36 In summary, we have identified mutations in DONSON as a commo
37 In summary, we have identified novel CL/P risk loci and sugge
38 In summary, we have identified several novel genes influencin
39 In summary, we have identified several previously unrecognize
40 In summary, we have identified SGPL1 mutations in humans that
41 In summary, we have implemented, validated and tested the ME-
42 In summary, we have obtained decolorized myocardial tissue su
43 In summary, we have reconstituted the essential core of the g
44 In summary, we have shown that calcineurin Abeta and SORLA ar
45 In summary, we have successfully characterized the force indu
46 In summary, we have successfully validated the disease-causin
47 In summary, we have uncovered a novel human mitochondrial KMT
48 In summary, we have uncovered key architectural features in t
49 In summary, we have uncovered the existence of high-dimension
50 In summary, we have utilized single-molecule detection to unr